GlassScriptPhysician profile
Edith Gonzalez-Werner
NPI 1699810838
$5,989.46
in general payments reported to CMS, 2019-2025
32 companies · $21.82 in 2025
The $21.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $1,564 · 2021: $1,977 · 2022: $524 · 2023: $963 · 2024: $134 · 2025: $21.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.91 | 2020-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $600.57 | 2019-2024 | Farxiga, Airsupra |
| Daiichi Sankyo INC. | $525.01 | 2019-2022 | |
| Amgen INC. | $488.86 | 2020-2023 | Repatha, Otezla |
| Lilly USA, LLC | $394.08 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $367.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.66 | 2019-2024 | Tradjenta, Jardiance |
| Amarin Pharma, INC. | $293.23 | 2020-2021 | |
| Therapeuticsmd, INC. | $254.30 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $248.71 | 2023-2024 | |
| Galderma Laboratories, L.P. | $245.94 | 2021-2023 | |
| Glaxosmithkline, LLC. | $225.01 | 2019-2023 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $187.14 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $186.28 | 2021 | |
| Allergan, INC. | $164.67 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $110.81 | 2019-2022 | |
| Dexcom, INC. | $109.92 | 2021-2022 | |
| Abbvie INC. | $91.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $91.28 | 2019-2021 | |
| Astellas Pharma US INC | $61.91 | 2019-2020 | |
| Pfizer INC. | $54.41 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $43.06 | 2023 | Quviviq |
| Eisai INC. | $39.66 | 2020-2021 | |
| Abbott Laboratories | $36.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.03 | 2021-2022 | |
| Medtronic, INC. | $29.08 | 2022 | |
| Corcept Therapeutics | $21.82 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $21.22 | 2019 | |
| Assertio Therapeutics, INC. | $16.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.39 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2021 | |
| Sanofi Pasteur INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Gonzalez-Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.